Zerotuss LS Oral Drops is a combination expectorant and bronchodilator formulation containing Ambroxol (7.5 mg), Levosalbutamol (0.25 mg), and Guaifenesin (12.5 mg) per dose. Ambroxol acts as a mucolytic agent, facilitating the breakdown and clearance of mucus from the respiratory tract by enhancing mucociliary transport and reducing sputum viscosity. Levosalbutamol, a selective beta-2 adrenergic receptor agonist, provides bronchodilation by relaxing the smooth muscles of the airways, thereby improving airflow and alleviating bronchospasm associated with conditions such as asthma and chronic obstructive pulmonary disease (COPD). Guaifenesin serves as an expectorant, promoting the secretion of less viscous mucus, which aids in productive cough and effective clearance of bronchial secretions. This combination is indicated for the symptomatic relief of cough and congestion associated with respiratory tract infections, bronchitis, and other conditions characterized by increased mucus production and bronchospasm. Zerotuss LS Oral Drops should be used as directed by a healthcare professional, with caution advised in patients with hypersensitivity to any component, cardiovascular disorders, or hyperthyroidism. The product offers a multi-mechanistic approach to managing respiratory symptoms, enhancing patient comfort and respiratory function.